Krónikus hepatitis C-vírus-fertozött betegek pegilált interferon-alfa-2a-és ribavirinkezelésének biztonságossága a hazai tapasztalatok alapján

Translated title of the contribution: The safety of treatment with pegylated interferon-alpha-2A and ribavirin in patients with chronic hepatitis c infection, based on Hungarian experience

Werling Klára, Dalmi Lajos, Gervain Judit, Horváth Gábor, Nagy István, Nemesánszky Elemér, Ribiczey Pál, L. Telegdy, Varga Márta, Tornai István, Z. Tulassay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

INTRODUCTION - Adverse effects of treatment for chronic C virus hepatitis present an important problem both for the patient and the clinician. The reduction of drug doses or the suspension of therapy lessen the likelihood of recovery. PATIENTS, METHODS - Between 2001 and 2004, 66 patients with chronic hepatitis C received 180 μg pegylated interferon-alpha-2a per week and 800-1200 mg ribavirin per day, 6 of whom for 24 weeks and 60 patients for 48 weeks. During treatment, patients were closely followed in order to recognize any adverse effects early. RESULTS - Of the patients treated for 48 weeks, 48.3% developed adverse effects, with changes in the differential in 41.7%, and anaemia, low platelet count, neutropenia in similar rates. Further side effects included cardiac complications, skin symptoms, persisting high fever, autoimmune thyroiditis and liver failure, altogether in 9 cases. Dose reduction or temporary suspension of pegylated interferon-alpha-2a was necessary in 21 cases (31.7%), while complete cessation of this treatment was decided in 7 cases, most of them because of blood count changes. The 1000 to 1200 mg per day ribavirin had to be reduced in 30.8% of patients, while treatment was stopped in 3 cases. Long-term virological remission occurred in 48% of patients who received treatment for 48 weeks, whereas no such result was observed among any of those treated for 24 weeks. CONCLUSION - Adverse effects of variable severity developed in nearly half of the patients with chronic hepatitis C infection who received antiviral treatment for 48 weeks, but treatment had to be stopped in only a small proportion of this group. Early treatment of adverse effects can prevent the need to cease therapy and may improve its efficiency.

Original languageHungarian
Pages (from-to)421-426
Number of pages6
JournalLege Artis Medicinae
Volume17
Issue number6-7
Publication statusPublished - Jul 2007

Fingerprint

Ribavirin
Chronic Hepatitis
Safety
Infection
Chronic Hepatitis C
Therapeutics
Suspensions
peginterferon alfa-2a
Autoimmune Thyroiditis
Withholding Treatment
Liver Failure
Neutropenia
Platelet Count
Antiviral Agents
Anemia
Fever
Viruses
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krónikus hepatitis C-vírus-fertozött betegek pegilált interferon-alfa-2a-és ribavirinkezelésének biztonságossága a hazai tapasztalatok alapján. / Klára, Werling; Lajos, Dalmi; Judit, Gervain; Gábor, Horváth; István, Nagy; Elemér, Nemesánszky; Pál, Ribiczey; Telegdy, L.; Márta, Varga; István, Tornai; Tulassay, Z.

In: Lege Artis Medicinae, Vol. 17, No. 6-7, 07.2007, p. 421-426.

Research output: Contribution to journalArticle

Klára, W, Lajos, D, Judit, G, Gábor, H, István, N, Elemér, N, Pál, R, Telegdy, L, Márta, V, István, T & Tulassay, Z 2007, 'Krónikus hepatitis C-vírus-fertozött betegek pegilált interferon-alfa-2a-és ribavirinkezelésének biztonságossága a hazai tapasztalatok alapján', Lege Artis Medicinae, vol. 17, no. 6-7, pp. 421-426.
Klára, Werling ; Lajos, Dalmi ; Judit, Gervain ; Gábor, Horváth ; István, Nagy ; Elemér, Nemesánszky ; Pál, Ribiczey ; Telegdy, L. ; Márta, Varga ; István, Tornai ; Tulassay, Z. / Krónikus hepatitis C-vírus-fertozött betegek pegilált interferon-alfa-2a-és ribavirinkezelésének biztonságossága a hazai tapasztalatok alapján. In: Lege Artis Medicinae. 2007 ; Vol. 17, No. 6-7. pp. 421-426.
@article{d68254dc306441f0b994164ea0e2f98c,
title = "Kr{\'o}nikus hepatitis C-v{\'i}rus-fertoz{\"o}tt betegek pegil{\'a}lt interferon-alfa-2a-{\'e}s ribavirinkezel{\'e}s{\'e}nek biztons{\'a}goss{\'a}ga a hazai tapasztalatok alapj{\'a}n",
abstract = "INTRODUCTION - Adverse effects of treatment for chronic C virus hepatitis present an important problem both for the patient and the clinician. The reduction of drug doses or the suspension of therapy lessen the likelihood of recovery. PATIENTS, METHODS - Between 2001 and 2004, 66 patients with chronic hepatitis C received 180 μg pegylated interferon-alpha-2a per week and 800-1200 mg ribavirin per day, 6 of whom for 24 weeks and 60 patients for 48 weeks. During treatment, patients were closely followed in order to recognize any adverse effects early. RESULTS - Of the patients treated for 48 weeks, 48.3{\%} developed adverse effects, with changes in the differential in 41.7{\%}, and anaemia, low platelet count, neutropenia in similar rates. Further side effects included cardiac complications, skin symptoms, persisting high fever, autoimmune thyroiditis and liver failure, altogether in 9 cases. Dose reduction or temporary suspension of pegylated interferon-alpha-2a was necessary in 21 cases (31.7{\%}), while complete cessation of this treatment was decided in 7 cases, most of them because of blood count changes. The 1000 to 1200 mg per day ribavirin had to be reduced in 30.8{\%} of patients, while treatment was stopped in 3 cases. Long-term virological remission occurred in 48{\%} of patients who received treatment for 48 weeks, whereas no such result was observed among any of those treated for 24 weeks. CONCLUSION - Adverse effects of variable severity developed in nearly half of the patients with chronic hepatitis C infection who received antiviral treatment for 48 weeks, but treatment had to be stopped in only a small proportion of this group. Early treatment of adverse effects can prevent the need to cease therapy and may improve its efficiency.",
keywords = "Adverse effects, Chronic hepatitis C infection, Pegylated interferon-alpha-2a, Ribavirin",
author = "Werling Kl{\'a}ra and Dalmi Lajos and Gervain Judit and Horv{\'a}th G{\'a}bor and Nagy Istv{\'a}n and Nemes{\'a}nszky Elem{\'e}r and Ribiczey P{\'a}l and L. Telegdy and Varga M{\'a}rta and Tornai Istv{\'a}n and Z. Tulassay",
year = "2007",
month = "7",
language = "Hungarian",
volume = "17",
pages = "421--426",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - Krónikus hepatitis C-vírus-fertozött betegek pegilált interferon-alfa-2a-és ribavirinkezelésének biztonságossága a hazai tapasztalatok alapján

AU - Klára, Werling

AU - Lajos, Dalmi

AU - Judit, Gervain

AU - Gábor, Horváth

AU - István, Nagy

AU - Elemér, Nemesánszky

AU - Pál, Ribiczey

AU - Telegdy, L.

AU - Márta, Varga

AU - István, Tornai

AU - Tulassay, Z.

PY - 2007/7

Y1 - 2007/7

N2 - INTRODUCTION - Adverse effects of treatment for chronic C virus hepatitis present an important problem both for the patient and the clinician. The reduction of drug doses or the suspension of therapy lessen the likelihood of recovery. PATIENTS, METHODS - Between 2001 and 2004, 66 patients with chronic hepatitis C received 180 μg pegylated interferon-alpha-2a per week and 800-1200 mg ribavirin per day, 6 of whom for 24 weeks and 60 patients for 48 weeks. During treatment, patients were closely followed in order to recognize any adverse effects early. RESULTS - Of the patients treated for 48 weeks, 48.3% developed adverse effects, with changes in the differential in 41.7%, and anaemia, low platelet count, neutropenia in similar rates. Further side effects included cardiac complications, skin symptoms, persisting high fever, autoimmune thyroiditis and liver failure, altogether in 9 cases. Dose reduction or temporary suspension of pegylated interferon-alpha-2a was necessary in 21 cases (31.7%), while complete cessation of this treatment was decided in 7 cases, most of them because of blood count changes. The 1000 to 1200 mg per day ribavirin had to be reduced in 30.8% of patients, while treatment was stopped in 3 cases. Long-term virological remission occurred in 48% of patients who received treatment for 48 weeks, whereas no such result was observed among any of those treated for 24 weeks. CONCLUSION - Adverse effects of variable severity developed in nearly half of the patients with chronic hepatitis C infection who received antiviral treatment for 48 weeks, but treatment had to be stopped in only a small proportion of this group. Early treatment of adverse effects can prevent the need to cease therapy and may improve its efficiency.

AB - INTRODUCTION - Adverse effects of treatment for chronic C virus hepatitis present an important problem both for the patient and the clinician. The reduction of drug doses or the suspension of therapy lessen the likelihood of recovery. PATIENTS, METHODS - Between 2001 and 2004, 66 patients with chronic hepatitis C received 180 μg pegylated interferon-alpha-2a per week and 800-1200 mg ribavirin per day, 6 of whom for 24 weeks and 60 patients for 48 weeks. During treatment, patients were closely followed in order to recognize any adverse effects early. RESULTS - Of the patients treated for 48 weeks, 48.3% developed adverse effects, with changes in the differential in 41.7%, and anaemia, low platelet count, neutropenia in similar rates. Further side effects included cardiac complications, skin symptoms, persisting high fever, autoimmune thyroiditis and liver failure, altogether in 9 cases. Dose reduction or temporary suspension of pegylated interferon-alpha-2a was necessary in 21 cases (31.7%), while complete cessation of this treatment was decided in 7 cases, most of them because of blood count changes. The 1000 to 1200 mg per day ribavirin had to be reduced in 30.8% of patients, while treatment was stopped in 3 cases. Long-term virological remission occurred in 48% of patients who received treatment for 48 weeks, whereas no such result was observed among any of those treated for 24 weeks. CONCLUSION - Adverse effects of variable severity developed in nearly half of the patients with chronic hepatitis C infection who received antiviral treatment for 48 weeks, but treatment had to be stopped in only a small proportion of this group. Early treatment of adverse effects can prevent the need to cease therapy and may improve its efficiency.

KW - Adverse effects

KW - Chronic hepatitis C infection

KW - Pegylated interferon-alpha-2a

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=34547186547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547186547&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34547186547

VL - 17

SP - 421

EP - 426

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -